Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce A Cree

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 21, 2025
Investigating the impact of age on neurodegeneration after optic neuritis in multiple sclerosis using optical coherence tomographyHenriette Km Reinsberg, Frederike C Oertel, Daniel Casillas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 23, 2023
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorderOrhan Aktas, Hans-Peter Hartung, Michael A Smith, et al.
Lancet (London, England)|October 15, 2017
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trialAri J Green, Jeffrey M Gelfand, Bruce A Cree, et al.
Annals of Neurology|March 2, 2022
Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS"Antje Bischof, Nico Papinutto, Anisha Keshavan, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 21, 2025
Investigating the impact of age on neurodegeneration after optic neuritis in multiple sclerosis using optical coherence tomographyHenriette Km Reinsberg, Frederike C Oertel, Daniel Casillas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 23, 2023
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorderOrhan Aktas, Hans-Peter Hartung, Michael A Smith, et al.
Lancet (London, England)|October 15, 2017
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trialAri J Green, Jeffrey M Gelfand, Bruce A Cree, et al.
Annals of Neurology|March 2, 2022
Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS"Antje Bischof, Nico Papinutto, Anisha Keshavan, et al.
Pageof 2